期刊
ADVANCED HEALTHCARE MATERIALS
卷 9, 期 10, 页码 -出版社
WILEY
DOI: 10.1002/adhm.201901875
关键词
cholangiocarcinoma diagnostics; circulating tumor cells; glycosaminoglycan; integrated microfluidic platforms; magnetic beads
资金
- National Health Research Institutes of Taiwan [NHRI-EX107-10728EI]
- Taiwan's Ministry of Health and Welfare [MOHW107-TDU-B-211-123003]
- Higher Education Support Project of Taiwan's Ministry of Education [107Q2713E1]
- Ministry of Science and Technology of Taiwan [MOST 106-2745-M-001-001-ASP, MOST 106-2113-M-259-009, MOST-106-2113-M-001-009-MY2, MOST 106-2119-M-007-008]
- Academia Sinica [AS-IA-104-L04]
The search of alternative approaches to epithelial cell adhesion molecule (EpCAM), for the isolation of circulating tumor cells (CTC), is on the rise. This work attempts at evaluating the feasibility of using a new glycosaminoglycan, SCH45, as a probe to isolate CTCs from the peripheral blood of 65 advanced/metastatic cholangiocarcinoma (CCA) patients. The positive enrichment of CTCs from 1 mL of blood using SCH45-bound magnetic beads and subsequent staining on an integrated microfluidic platform is demonstrated. Results detailing CTC concentrations averaging >= 1 CTCs mL(-1) of blood are shown, and a conventional protein biomarker, EpCAM, has been used to corroborate the finding that 100% of the patients possess CTCs in their blood. Studies detailing the use of CTCs in the prognostic monitoring and treatment effectiveness of advanced/metastatic CCA are scarce, and the isolation of CTCs from all CCA patients tested has not been reported yet. A strong correlation between CTC counts and disease progression at the time of and/or in advance of radiographic imaging in patients receiving chemotherapy is also reported. This study is one of its kind with the new probe and reduced sample volume and has potential for use in CCA diagnosis and prognosis in the near future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据